Welcome to our dedicated page for Pennant Group SEC filings (Ticker: PNTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pennant Group, Inc. filings document the public reporting of a healthcare services holding company with operating subsidiaries in home health, hospice, home care and senior living. Recent Form 8-K reports furnish quarterly and annual results, Regulation FD investor materials, material agreements and amendments tied to acquisitions and financing arrangements.
Proxy filings cover governance, board matters, executive compensation and shareholder voting items. Other material-event amendments provide acquisition-related financial statements and pro forma information, while credit agreement disclosures describe term loans, leverage and coverage covenants, restrictions on indebtedness, liens, dispositions and restricted payments, and healthcare-law-related default provisions.
Pennant Group, Inc. director John G. Nackel reported an equity award of 1,900 shares of common stock on January 15, 2026, at a stated price of $0 per share. These shares vest in three annual installments beginning January 15, 2027, meaning the award is earned over time rather than all at once.
After this grant, Nackel beneficially owns 170,765 common shares directly. He also has indirect beneficial ownership of 2,700 common shares held by the Nackel Family Trust dated June 30, 1997, over which he and his spouse share voting and investment power.
Pennant Group, Inc. director Morris Gregory K Sr. reported receiving a grant of company common stock. On January 15, 2026, he was awarded 1,900 shares of Pennant Group common stock at a reported price of $0 per share, indicating a stock award rather than an open-market purchase. After this transaction, he beneficially owned 33,500 common shares in total on a direct basis.
The filing notes that these awarded shares vest in three annual installments beginning January 15, 2027, meaning the director gains full ownership rights to the award gradually over three years.
The Pennant Group director reports a new stock award. Director Barry M. Smith received 1,900 shares of Pennant Group, Inc. common stock on January 15, 2026 in a transaction coded "A," which indicates an acquisition, at a stated price of $0 per share. According to the filing, these shares vest in three equal annual installments starting on January 15, 2027, meaning the award is structured to vest over three years. After this grant, Smith beneficially owns 98,699 shares of Pennant Group common stock in direct ownership.
Van Berkom & Associates Inc., a Canadian investment adviser, reports beneficial ownership of 3,112,812 common shares of Pennant Group, Inc., representing 9.0% of the outstanding class as of September 30, 2025. The firm has sole power to vote and dispose of all these shares and no shared voting or dispositive power.
This is Amendment No. 2 to a Schedule 13G and is being filed to correct prior disclosure. Van Berkom explains that an earlier Schedule 13G was filed based on the belief it no longer beneficially owned Pennant shares, but on further review it had continuously held more than 5% but less than 10% of the class as of that date, so no filing was required. The amendment clarifies that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Pennant Group.
The Pennant Group, Inc. filed Amendment No. 2 to an earlier current report to add detailed financial information for its completed acquisition of certain Amedisys and UnitedHealth subsidiaries that provide home health, hospice and palliative care services.
The update supplies audited abbreviated financial statements for the acquired Amedisys and UnitedHealth subsidiaries for the year ended December 31, 2024, and unaudited abbreviated financial statements for the six months ended June 30, 2025. It also includes unaudited pro forma condensed combined financial statements for The Pennant Group and the acquired businesses for the same periods.
The company emphasizes that the pro forma data, filed as Exhibit 99.5, are illustrative, prepared under SEC rules, and are not intended to represent actual historical results or to predict future performance following the transaction.
Pennant Group (PNTG) executive Kirk Cheney, EVP, General Counsel and Corporate Secretary, reported an insider transaction on 11/11/2025. He acquired 3,800 shares of common stock via an option exercise (Code M) at $15.09 per share.
After the transaction, he beneficially owned 16,920 common shares directly. The exercised employee stock option carried a $15.09 exercise price, first became exercisable on 10/01/2020, and expires on 10/01/2029. Following the exercise, 4,200 derivative securities (stock options) remained beneficially owned.
The Pennant Group (PNTG) entered a material financing amendment. On November 3, 2025, the company added an incremental Term Loan A of $100,000,000 under its Amended and Restated Credit Agreement with Truist Bank and additional lenders.
The new term loans bear the same interest rate and have the same maturity date as the company’s revolving facility. Pennant used the proceeds to refinance a portion of outstanding revolver borrowings and to pay related fees and expenses, effectively shifting debt from revolving to term while keeping pricing and maturity aligned.
The credit facility includes customary representations and covenants, including financial tests based on the Leverage Ratio and the Interest/Rent Coverage Ratio, and limits on additional indebtedness, liens, significant corporate changes, dispositions, and restricted payments. Standard events of default apply, including payment defaults, certain healthcare law violations, change in control, bankruptcy, and other operational covenants; if uncured, lenders may accelerate the debt.
The Pennant Group (PNTG) entered a material financing amendment. On November 3, 2025, the company added an incremental Term Loan A of $100,000,000 under its Amended and Restated Credit Agreement with Truist Bank and additional lenders.
The new term loans bear the same interest rate and have the same maturity date as the company’s revolving facility. Pennant used the proceeds to refinance a portion of outstanding revolver borrowings and to pay related fees and expenses, effectively shifting debt from revolving to term while keeping pricing and maturity aligned.
The credit facility includes customary representations and covenants, including financial tests based on the Leverage Ratio and the Interest/Rent Coverage Ratio, and limits on additional indebtedness, liens, significant corporate changes, dispositions, and restricted payments. Standard events of default apply, including payment defaults, certain healthcare law violations, change in control, bankruptcy, and other operational covenants; if uncured, lenders may accelerate the debt.
The Pennant Group (PNTG) reported third‑quarter 2025 results with revenue of $229.0 million versus $180.7 million a year ago. Income from operations was $10.2 million compared to $10.8 million, and net income attributable to the company was $6.1 million versus $6.2 million. Diluted EPS was $0.17 versus $0.20.
Home Health and Hospice revenue reached $173.5 million and Senior Living $53.9 million. Segment Adjusted EBITDAR from Operations improved to $44.4 million, led by $29.1 million in Home Health and Hospice and $15.3 million in Senior Living. Year to date, operating cash flow was $27.3 million.
The company expanded through acquisitions in 2025, including part two of Signature Group (contributing $48.8 million revenue and $8.9 million operating income year to date) and additional home health deals. Cash was $2.3 million, long‑term debt was $26.0 million under the revolving credit facility, and total assets were $753.6 million. As of November 3, 2025, 34,593,720 common shares were outstanding. Subsequent to quarter end, Pennant closed a $146.5 million acquisition of home health, hospice, and home care locations and added a $100 million incremental term loan under its credit agreement.
The Pennant Group (PNTG) reported third‑quarter 2025 results with revenue of $229.0 million versus $180.7 million a year ago. Income from operations was $10.2 million compared to $10.8 million, and net income attributable to the company was $6.1 million versus $6.2 million. Diluted EPS was $0.17 versus $0.20.
Home Health and Hospice revenue reached $173.5 million and Senior Living $53.9 million. Segment Adjusted EBITDAR from Operations improved to $44.4 million, led by $29.1 million in Home Health and Hospice and $15.3 million in Senior Living. Year to date, operating cash flow was $27.3 million.
The company expanded through acquisitions in 2025, including part two of Signature Group (contributing $48.8 million revenue and $8.9 million operating income year to date) and additional home health deals. Cash was $2.3 million, long‑term debt was $26.0 million under the revolving credit facility, and total assets were $753.6 million. As of November 3, 2025, 34,593,720 common shares were outstanding. Subsequent to quarter end, Pennant closed a $146.5 million acquisition of home health, hospice, and home care locations and added a $100 million incremental term loan under its credit agreement.
The Pennant Group (PNTG) furnished an update on its third‑quarter performance. On November 5, 2025, the company issued a press release reporting financial results for the quarter ended September 30, 2025, and made the release available as Exhibit 99.1. The company also plans to post an updated investor presentation on its website for upcoming meetings. The information under Items 2.02 and 7.01, including Exhibit 99.1, was furnished and is not deemed filed or incorporated by reference except as specifically stated.
The Pennant Group (PNTG) furnished an update on its third‑quarter performance. On November 5, 2025, the company issued a press release reporting financial results for the quarter ended September 30, 2025, and made the release available as Exhibit 99.1. The company also plans to post an updated investor presentation on its website for upcoming meetings. The information under Items 2.02 and 7.01, including Exhibit 99.1, was furnished and is not deemed filed or incorporated by reference except as specifically stated.
Pennant Group (PNTG) director reported an equity award. On 10/15/2025, the reporting person acquired 1,900 shares of common stock at a reported price of $0. Following the transaction, the individual beneficially owns 96,799 shares, held directly.
The filing states these shares vest in three annual installments beginning October 15, 2026. This is a routine director equity grant and does not reflect an open‑market purchase.